Proven efficacy against PCV2 and M.hyo

suvaxyn circo+mh rtu significantly protects against post-challenge viraemia^1,2,3

viraemia 1

viraemia 2

viraemia 3

suvaxyn circo+mh rtu reduces postchallenge pcv2 faecal shedding^1,2

faecal 1 faecal 2

suvaxyn circo+mh rtu significantly reduces pcv2 pathology^1,2

tissue 1

suvaxyn circo+mh rtu reduces lung lesions caused by m.hyo^4,5,6

lung lesions 1

^{1. Data on file, Study Report No. B822R-US-12-046, Zoetis Inc.
2. Data on file, Study Report No. B824R-US-13-118, Zoetis Inc.
3. Data on file, Study Report No. B826C-NL-13-167, Zoetis Inc.
4. Data on file, Study Report No. B823R-US-13-136, Zoetis Inc.
5. Data on file, Study Report No. B824R-US-14-359, Zoetis Inc.
6. Data on file, Study Report No. B824R-US-15-505, Zoetis Inc.}

You are leaving the country website to access another site in the group.

Regulatory constraints and medical practices vary from country to country. Consequently, the information provided on the site in which you enter may not be suitable for use in your country.